Mary Townsend retweeted
New on Paxlovid relapse, being reported w/ increased frequency as use has risen
In-depth assessment of a case
No sign of resistance or lack of neutralizing antibody. "most likely possibility for the observed recrudescence is insufficient drug exposure"
researchsquare.com/article/r…
Mary Townsend retweeted
Breaking News: The CDC director recommended that Pfizer booster shots include people at risk because of their jobs, overruling her own agency’s advisers. nyti.ms/3o400Su
Mary Townsend retweeted
Bad for morale for those who need a different kind of "boost" after many months of front-line work ... yes, including me and my physician spouse, @SaxCarolyn.
Do not think we are alone in these feelings
😢
The final ACIP vote in support of recommendation #4 does not pass. Thus the committee DOES NOT support a booster for persons 18-64 who are in occupational or institutional settings where the burden of COVID-19 infection and risk of transmission are high.
Mary Townsend retweeted
Interesting results to be shared at #IAS2021 this week on HIV-associated crypto meningitis treatments. theprogramme.ias2021.org/Abs… @ambitioncm2020 @drdavidlawrence @APTlivuni @AchitaSingh @Graemein @boulware_dr @dmeya
@TugumeLillian
@timotheebc @yawjoshua @JNJarvis76 @AngelaLoyse
This quoted post is unavailable.
Mary Townsend retweeted
#Remdesivir 5 vs. 10 day treatment trial for #severe #COVID19 is out!
- 5 days enough for most patients (shorter is good)
- Outcome strongly influenced by severity of disease within stratum (earlier is better)
- Outcomes comparable to #ACTT1 overall
link:nejm.org/doi/full/10.1056/NE…
Mary Townsend retweeted
#Remdesivir begins distribution in the #USA today via #EUA.
I thought would write down some practical #tips based on my #qualitative anecdotal experience after personally treating close to 200 patients with #COVID19.
For quantitative results, wait for the papers¬—thread
Mary Townsend retweeted
I don’t usually rant on social media. However, after a week of service in the ICU, I’d like to get a few things off my chest. #COVID19 (1/10)
Mary Townsend retweeted
More fascinating and clear #COVID19 Insights from Dr. Bill Rodriguez. Definitely worth your time. covid19-insights.squarespace…
Mary Townsend retweeted
.@NC_Governor: I know at least one district is using school buses to deliver daily meals to children on bus routes, and I commend this innovative thinking. #covid19nc
Mary Townsend retweeted
When the history is written of how we responded to this threat, this graph will be featured prominently. ID clinicians, epidemiologists, scientists have called for more testing for weeks!
But ... water under the bridge. Time to move to next phase, which is aggressive mitigation.
This quoted post is unavailable.
Mary Townsend retweeted
Excellent summary of the current coronavirus testing morass here in the US. Put this on your "must-read" list for today, and continue to hope that this painful phase will be over soon so that we can have greater clarity about the #COVID2019 situation here.
Testing 1, 2, oops. Curious why the U.S. coronavirus diagnostic effort went off the rails and how it's attempting to get back on track? sciencemag.org/news/2020/02/…
Mary Townsend retweeted
Hey @ResidentFOX , my services to help you talk about infectious diseases without sounding dumb are available at a very reasonable price.
Mary Townsend retweeted
Congrats to ID-PRN members @julie_justo and @BBookstaver_USC for their recent pub in IJAA!
NEW in IJAA 🤳: We found sig. seasonal variation 📊 in antimicrobial resistance rates of E. coli BSI isolates to 💊 4 common abx 💊 used in the community. Article is open access til July 31 at link below:
authors.elsevier.com/a/1ZCpr…
Great collab: @ASC_SCarolina @UofSCSOM @UofSCPharm
Mary Townsend retweeted
ICYMI: the collaborative @SIDPharm @accpinfdprn @CLSI_LabNews CE program is posted on the SIDPEC site at: sidp.org/SIDPEC - scroll down to find it & enjoy this great discussion of incorporating CLSI 2019 updates in your stewardship program. #ASMicrobe #ASM2019
Mary Townsend retweeted
"Ten of 12 antibiotics launched in the US in the past decade (not all of them breakthrough products) are achieving US sales of less than $100m a year. This barely covers the cost of keeping them on the market, let alone recouping investments."
Mary Townsend retweeted
NEW 🔥🔥 @IDpharmresearch in OFID Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections treated with Vancomycin. Vancomycin plus beta-lactams debate continues.🤔 academic.oup.com/ofid/advanc…
Mary Townsend retweeted
NEW 🔥🔥🔥Just published in @PharmacoJournal
@BrianTsuji @jpogue1 @Keith_S_Kaye
International Consensus Guidelines for the Optimal Use of the Polymyxins: Recommendations from @ACCP, @ESCMID, @IDSAInfo, @ISAP_org, and @SIDPharm. @SCCM accpjournals.onlinelibrary.w…
Mary Townsend retweeted
the debate continues... looking forward to reading this one! @JClinMicro jcm.asm.org/cgi/content/long… @SIDPharm
